On May 11, 2024, Zydus Lifesciences Limited informed the stock exchanges that the company had got final approval from the United States Food and Drug Administration (US FDA) to market Dexamethasone Tablets USP, 1 mg. Dexamethasone is used to treat a range of conditions, including arthritis, allergic reactions, skin diseases, blood/hormone disorders, breathing difficulties, bowel …